ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Conversation With The Cancer Letter: How ASCO’s Guideline Differs—And Why

July 20, 2012

Ten-Year Breast Cancer Survival Improved In Past 60 Years, MD Anderson Study Finds

October 29, 2010

Seven New Initiatives For NIH Common Fund

February 26, 2010

DCPC Board Approves New Intramural Laboratory for Diet And Nutrition; NCAB to Consider It Next

May 22, 1987

Draft FY 1993 Bypass Budget Seeks $2.7 Billion, Stabilization Of Groups, Centers, And Prevention

May 10, 1991

Panel Clear On Breast Conservation, Not On Adjuvant Therapy For Node

June 29, 1990